This reflection was written by Jennifer Levin Carter, MD, MPH, MBA, Founder and CEO of Medzown, Inc., and a member of the TCF Board of Directors.
I do a lot of work in the rare disease and rare cancer industries, and TargetCancer Foundation (TCF) is a standout organization making a remarkable impact on expanding the opportunities for treatment for patients with rare cancers. Under Jim Palma’s impressive leadership, TCF has started the first and only fully remote rare cancer clinical trial (TCF-001 TRACK) bringing tumor genomic testing to patients all over the country. These patients would not otherwise have access to the data on their tumors which can directly impact their survival. The study is not only uncovering additional treatment options for patients but also moving the whole industry forward.
TCF’s commitment to transforming care for patients with rare cancer is also powerfully demonstrated in the Think Tank on Advancing Precision Medicine in Rare Cancers and Industry Roundtable. In the midst of a busy conference season, these events are the favorites of thought leaders and industry partners from all over the US and globally.
It is a great honor to be a board member of such an impactful organization. Please consider how you can support TCF’s ongoing work to grow our mission to bring more and better treatment options to patients with rare cancers.